Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Jul;38(7):1644–1646. doi: 10.1128/aac.38.7.1644

Decreased counts of blood neutrophils, monocytes, and platelets in human immunodeficiency virus-infected children and young adults treated with diethyldithiocarbamate.

J L Shenep 1, W T Hughes 1, P M Flynn 1, P K Roberson 1, F G Behm 1, G H Fullen 1, S G Kovnar 1, K P Guito 1, T O Brodkey 1
PMCID: PMC284606  PMID: 7979299

Abstract

Nineteen young human immunodeficiency virus-infected patients were randomized to receive 400 mg of oral diethyldithiocarbamate (DTC) per m2 or placebo weekly for 12 weeks. Changes in blood CD4+ lymphocytes were not significantly different between groups. However, neutrophil, monocyte, and platelet counts consistently decreased during DTC treatment, suggesting DTC-mediated myelosuppression.

Full text

PDF
1644

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BIZZI L., GARATTINI S., MOR C. Protezione verso la tossicità acuta da rame mediante l'impiego di sostanze chelanti. Boll Soc Ital Biol Sper. 1955 Jul-Aug;31(7-8):867–870. [PubMed] [Google Scholar]
  2. Corke C. F. The influence of diethyl-dithiocarbamate ('Imuthiol') on mononuclear cells in vitro. Int J Immunopharmacol. 1984;6(3):245–247. doi: 10.1016/0192-0561(84)90023-7. [DOI] [PubMed] [Google Scholar]
  3. Hersh E. M., Brewton G., Abrams D., Bartlett J., Galpin J., Gill P., Gorter R., Gottlieb M., Jonikas J. J., Landesman S. Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo-controlled, multicenter study. JAMA. 1991 Mar 27;265(12):1538–1544. [PubMed] [Google Scholar]
  4. Hersh E. M., Funk C. Y., Ryschon K. L., Petersen E. A., Mosier D. E. Effective therapy of the LP-BM5 murine retrovirus-induced lymphoproliferative immunodeficiency disease with diethyldithiocarbamate. AIDS Res Hum Retroviruses. 1991 Jun;7(6):553–561. doi: 10.1089/aid.1991.7.553. [DOI] [PubMed] [Google Scholar]
  5. Lang J. M., Touraine J. L., Trepo C., Choutet P., Kirstetter M., Falkenrodt A., Herviou L., Livrozet J. M., Retornaz G., Touraine F. Randomised, double-blind, placebo-controlled trial of ditiocarb sodium ('Imuthiol') in human immunodeficiency virus infection. Lancet. 1988 Sep 24;2(8613):702–706. doi: 10.1016/s0140-6736(88)90184-5. [DOI] [PubMed] [Google Scholar]
  6. Lemarie E., Musset M., Charbonnier C., Renoux M., Renoux G. Clinical characterization of imuthiol. Methods Find Exp Clin Pharmacol. 1986 Jan;8(1):51–54. [PubMed] [Google Scholar]
  7. Reisinger E. C., Kern P., Ernst M., Bock P., Flad H. D., Dietrich M. Inhibition of HIV progression by dithiocarb. German DTC Study Group. Lancet. 1990 Mar 24;335(8691):679–682. doi: 10.1016/0140-6736(90)90802-c. [DOI] [PubMed] [Google Scholar]
  8. Rigas D. A., Eginitis-Rigas C., Head C. Biphasic toxicity of diethyldithiocarbamate, a metal chelation, to T lymphocytes and polymorphonuclear granulocytes: reversal by zinc and copper. Biochem Biophys Res Commun. 1979 May 28;88(2):373–379. doi: 10.1016/0006-291x(79)92058-8. [DOI] [PubMed] [Google Scholar]
  9. Sunderman F. W., Paynter O. E., George R. B. The effects of the protracted administration of the chelating agent, sodium diethyldithiocarbamate (dithiocarb). Am J Med Sci. 1967 Jul;254(1):24–34. doi: 10.1097/00000441-196707000-00003. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES